<3-Fluor-benzyliden>-cyanessigsaeure-aethylester | 19310-52-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: <3-Fluor-benzyliden>-cyanessigsaeure-aethylester
• 英文别名: 2-Cyano-3-(3-fluoro-phenyl)-acrylic acid ethyl ester；ethyl 2-cyano-3-(3-fluorophenyl)prop-2-enoate
• CAS: 19310-52-2
• 化学式: C₁₂H₁₀FNO₂
• mdl: MFCD08776671
• 分子量: 219.215
• InChiKey: KRAONHPSLKXRMO-UHFFFAOYSA-N

物化性质

• 熔点：
  86-88 °C(Solv: acetone (67-64-1); water (7732-18-5))
• 沸点：
  330.7±32.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  <3-Fluor-benzyliden>-cyanessigsaeure-aethylester 在 potassium cyanide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 2-(3-氟苯基)琥珀酸
  参考文献：
  名称：

  Discovery, stereospecific characterization and peripheral modification of 1-(pyrrolidin-1-ylmethyl)-2-[(6-chloro-3-oxo-indan)-formyl]-1,2,3,4-tetrahydroisoquinolines as novel selective κ opioid receptor agonists

  摘要：

  11a产生强效的外周止痛作用。

  DOI：

  10.1039/c5ob00350d
• 作为产物：
  描述：

  生成 丁硫醇 、 <3-Fluor-benzyliden>-cyanessigsaeure-aethylester
  参考文献：
  名称：

  Equilibrium reactions of n-butanethiol with some conjugated heteroenoid compounds

  摘要：

  2-苯甲酰-1,3-茚酮和含氰基苯甲基马隆酰亚胺、乙基苯甲基氰乙酸酯、苯甲基氰乙酸酰胺和苯甲基氰乙酸苯胺在25°C下与n-丁硫醇在20%乙醇-80% pH 7缓冲液中的反应速率过快，无法通过标准方法测量。平衡常数已经计算，并与Hammett σ和Taft σ*常数相关联。这些和其他与n-丁硫醇在相同实验条件下以可测速率几乎完全反应的双官能团系统的反应差异被归因于苯基对顺式官能团在反向反应中的参与。结果表明，n-丁硫醇通过1,4-机理加成于肉桂酮苯乙酮，讨论了这种亲核试剂与具有扩展共轭体系的类似化合物的反应。

  DOI：

  10.1139/v68-128

文献信息

• Stereoselective Synthesis of<i>trans</i>-4,5-Substituted 1,4,5,6-tetrahydropyridine-2-(olates)thiolates
  作者：A. M. Shestopalov、V. P. Litvinov、L. A. Rodinovskaya、Yu. A. Sharanin

  DOI：10.1055/s-1991-26477

  日期：——

  trans-4,5-Substituted 1,4,5,6-tetrahydropyridine-2-(olates)thiolates are prepared either from pyridinium salts and cyanoacetic acid derivatives or from pyridinium salts, aromatic aldehydes and ethyl cyanoacetate or cyanoacetamide in the presence of a base.

  反式-4,5-取代的 1,4,5,6-四氢吡啶-2-（橄榄酸盐）硫醇酯可由吡啶鎓盐和氰乙酸衍生物制备，或由吡啶鎓盐、芳香醛和氰乙酸乙酯或氰乙酰胺在碱存在下制备。
• Stereoselective cascade assembling of benzylidenecyanoacetates and 1,3-dimethylbarbituric acid into (1<i>R</i>*,2<i>S</i>*)-1-cyano-5,7-dialkyl-4,6,8-trioxo-2-aryl-5,7-diazaspiro[2.5]octane-1-carboxylates
  作者：Michail N. Elinson、Anatoly N. Vereshchagin、Alexander D. Korshunov、Fedor V. Ryzhkov、Mikhail P. Egorov

  DOI：10.1515/hc-2016-0190

  日期：2017.4.1

  3-dimethylbarbituric acid by the action of bromine in the presence of a base into substituted (barbituric acid)-5-spirocyclopropanes is described. The yields are in the range of 60%–75%. Nuclear magnetic resonance (NMR) studies indicate that this cascade transformation results in the stereoselective formation of spiro products with trans-configuration of aryl and alkoxycarbonyl substituents in the cyclopropane

  摘要描述了亚苄基氰基乙酸酯和 1,3-二甲基巴比妥酸在碱存在下通过溴作用生成取代的（巴比妥酸）-5-螺环丙烷的新型立体选择性级联反应。产率在 60%–75% 的范围内。核磁共振 (NMR) 研究表明，这种级联转化导致在环丙烷环中具有芳基和烷氧基羰基取代基的反式构型的螺产物的立体选择性形成。该产品是一类具有显着药理和生理活性的化合物。
• 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shimizu Kazuo

  公开号：US20100227864A1

  公开（公告）日：2010-09-09

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M) 2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  本发明提供了一种化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及以下通式（I）表示的具有黄嘌呤氧化酶抑制活性的5-成员杂环衍生物，其可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂、其前药或其盐。在公式（I）中，T表示硝基、氰基等；环J表示芳基或杂芳基；Q表示羧基、5-四唑基等；Y表示H、OH、NH2、卤素、卤代烷基等；X1和X2独立地表示CR2或N；R2表示H、烷基等；R1表示卤素、氰基、卤代烷基、A-D-E-G-L-M、-N（-D-L-M）2等，在公式中，A表示单键、O、S等；D、G和M独立地表示可选取代的烷基、环烷基、杂环烷基、芳基、杂芳基等；E和L独立地表示单键、O、S、COO、SO2等。
• 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Shimizu Kazuo

  公开号：US20120289506A1

  公开（公告）日：2012-11-15

  5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, —N(-D-L-M) 2 and the like, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  通式（I）所表示的5元杂环衍生物具有黄嘌呤氧化酶抑制活性，并且可作为预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前药或盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，其中A表示单键，O，S等；D，G和M分别表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。
• 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US08227500B2

  公开（公告）日：2012-07-24

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, haloalkyl and the like; X1 and X2 independently represent CR2 or N; R2 represents H, alkyl and the like; R1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M)2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO2 and the like.

  本发明提供了化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及下式（I）表示的5-成员杂环衍生物，其具有黄嘌呤氧化酶抑制活性，并可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前体药物或其盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，在公式中，A表示单键，O，S等；D，G和M独立地表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。